XOOMAR

Arcutis Biotherapeutics, Inc. (ARQT)

Every FINRA and SEC series the site collects for Arcutis Biotherapeutics, Inc.: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.

Download CSV

14.7M

Short interest

settlement 2026-08-14

8.0

Days to cover

+16.0% vs prior

56.2%

Short share of volume

2026-09-11

16

Fails to deliver

settlement 2026-08-11

-$2.3M

Insider flow, 90 days

0 buys, 15 sells

As of 2026-09-11.

Short interest

FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSON

As of 14 August 2026, short interest in ARQT is 14,717,905 shares, up 1,156,340 shares over the last month. Over the last 48 readings it ranged from 12,059,791 shares (28 November 2025) to 28,064,868 shares (15 October 2024). At the reported average volume of 1.8M shares a day that is 8.0 days to cover, elevated.

Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/arqt" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
PreviewDark previewAdd ?theme=dark to the src for a dark chart.
SettlementShares shortChangeAvg daily volumeDays to cover
2026-08-1414,717,905+16.0%1,830,9378.04
2026-07-3112,686,384-6.5%1,180,84210.74
2026-07-1513,561,565-3.3%1,451,7429.34
2026-06-3014,019,289-11.4%2,213,5036.33
2026-06-1515,820,721-2.5%1,575,14910.04
2026-05-2916,226,183-7.5%1,922,0918.44
2026-05-1517,547,517+4.0%2,403,7527.30
2026-04-3016,879,909+1.8%1,015,46516.62
2026-04-1516,583,496-1.3%1,061,97715.62
2026-03-3116,801,149+6.7%1,511,82011.11
2026-03-1315,753,892+3.0%1,253,80712.56
2026-02-2715,292,517-6.6%1,570,9229.73
2026-02-1316,379,683+2.3%1,165,13914.06
2026-01-3016,010,858+5.2%1,153,91713.88
2026-01-1515,221,587+1.4%1,810,5528.41
2025-12-3115,011,554+13.4%1,910,8327.86
2025-12-1513,235,954+9.8%1,952,8516.78
2025-11-2812,059,791-12.1%2,777,3744.34
2025-11-1413,717,750+1.8%2,515,0475.45
2025-10-3113,479,227-5.6%2,813,0704.79
2025-10-1514,276,026-1.2%2,150,0496.64
2025-09-3014,452,315-9.9%1,846,9097.83
2025-09-1516,049,099-5.7%1,810,0148.87
2025-08-2917,018,275-7.5%1,209,28414.07

Daily short volume

FINRA Reg SHO, last 60 sessions. JSON

As of 11 September 2026, the short share of ARQT volume is 56.2%, down 12.9 points over the last five sessions. Over the last 52 readings it ranged from 17.5% (7 July 2026) to 78.2% (27 August 2026). The latest reading is in line with the 30-session average of 57.1%, on 722K shares reported.

DateShort volumeTotal volumeShort shareExempt
2026-09-11406K722K56.2%9
2026-09-10486K802K60.6%1,700
2026-09-09479K791K60.6%115
2026-09-081.2M1.8M66.7%96
2026-09-04465K685K67.8%55
2026-09-03340K492K69.1%200
2026-09-02550K803K68.5%1
2026-09-01230K361K63.7%200
2026-08-31283K504K56.1%25
2026-08-28399K621K64.2%10,476
2026-08-27519K664K78.2%0
2026-08-26445K614K72.5%4,163
2026-08-25307K405K75.7%27
2026-08-24188K328K57.2%0
2026-08-21660K1.1M61.8%0
2026-08-201.0M1.7M59.0%900
2026-08-19145K279K51.9%0
2026-08-18296K866K34.2%800
2026-08-17170K488K34.7%125
2026-08-14145K443K32.8%0
2026-08-13316K635K49.7%840
2026-08-12317K503K63.0%0
2026-08-11150K291K51.6%123
2026-08-10497K755K65.8%68
2026-08-07584K988K59.1%4,941
2026-08-06683K1.3M51.9%1,131
2026-08-05307K689K44.5%2,064
2026-08-04117K333K35.0%0
2026-08-03190K427K44.5%186
2026-07-31255K451K56.6%0

Fails to deliver

SEC, by settlement date. JSON

As of 11 August 2026, the fails-to-deliver balance in ARQT is 16 shares, down 12,693 shares over the last settlement date. Over the last 48 readings it ranged from 1 share (29 December 2025) to 29,256 shares (24 November 2025). The latest reading sits at the bottom of that range.

SettlementShares failedPriceValue
2026-08-1116$25.92$415
2026-08-0412,709$25.94$330K
2026-07-296$28.42$171
2026-07-24500$27.33$14K
2026-07-23500$27.90$14K
2026-07-22500$28.26$14K
2026-07-16306$27.78$9K
2026-06-29361$27.00$10K
2026-06-242,607$26.27$68K
2026-06-1555$24.38$1K
2026-06-11797$23.23$19K
2026-06-09420$21.54$9K
2026-06-08465$21.23$10K
2026-06-051,902$21.95$42K
2026-06-03125$20.79$3K
2026-06-019$21.46$193
2026-04-3057$22.37$1K
2026-04-214,150$24.47$102K
2026-04-20175$24.53$4K
2026-04-14462$24.12$11K
2026-03-30990$21.22$21K
2026-03-181,449$22.72$33K
2026-03-1741$22.76$933
2026-03-061$23.97$24
2026-02-266$27.01$162
2026-02-257$26.98$189
2026-02-241$26.31$26
2026-01-2121,771$25.87$563K
2026-01-162,738$26.36$72K
2026-01-05542$29.00$16K

Insider trades

SEC Form 4, newest first, 50 of 100 shown. JSON

Insiders at ARQT reported 15 open-market sells worth $2.3M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Matsuda Masaru (See Remarks) on 2026-09-08.

DateInsiderTitleTypeSharesPriceValueOwned after
2026-09-08Matsuda MasaruSee RemarksSell10K$25.03$250K116K
2026-08-27Curran Terrien/aSell27K$25.03$677K24K
2026-08-27Curran Terrien/aOption exercise27K$8.63$233K51K
2026-08-27Curran Terrien/aSell11K$25.03$279K24K
2026-08-27Curran Terrien/aOption exercise11K$7.51$84K35K
2026-08-20Curran Terrien/aSell1K$26.04$28K24K
2026-08-20Curran Terrien/aOption exercise1K$7.51$8K25K
2026-08-19Burnett PatrickSee RemarksSell2K$27.00$46K118K
2026-08-17Welgus Howard G.n/aSell5K$26.18$124K36K
2026-08-17Welgus Howard G.n/aOption exercise2K$8.63$19K41K
2026-08-17Welgus Howard G.n/aOption exercise1K$7.51$8K39K
2026-08-17Welgus Howard G.n/aOption exercise822$6.52$5K38K
2026-08-12Burnett PatrickSee RemarksSell7K$26.08$175K119K
2026-08-12Burnett PatrickSee RemarksOption exercise7K$3.64$24K126K
2026-08-11Burnett PatrickSee RemarksSell8K$26.52$220K119K
2026-08-11Burnett PatrickSee RemarksOption exercise8K$3.64$30K128K
2026-08-03Burnett PatrickSee RemarksSell955$26.12$25K119K
2026-08-03Matsuda MasaruSee RemarksSell1K$26.12$32K126K
2026-08-03Watanabe ToddSee RemarksSell4K$26.12$114K717K
2026-07-15Peetz Christophern/aGrant4K$0.00$04K
2026-07-15Welgus Howard G.n/aSell5K$26.91$127K37K
2026-07-15Welgus Howard G.n/aOption exercise2K$8.63$19K42K
2026-07-15Welgus Howard G.n/aOption exercise1K$7.51$8K40K
2026-07-15Welgus Howard G.n/aOption exercise822$6.52$5K39K
2026-06-17Welgus Howard G.n/aSell635$25.67$16K38K
2026-06-15LIN SUE-JEANn/aSell5K$24.38$121K28K
2026-06-15Welgus Howard G.n/aSell4K$24.41$100K38K
2026-06-15Welgus Howard G.n/aOption exercise2K$8.63$19K42K
2026-06-15Welgus Howard G.n/aOption exercise1K$7.51$8K40K
2026-06-15Welgus Howard G.n/aOption exercise822$6.52$5K39K
2026-06-05Heron Patrick Jn/aGrant6K$0.00$032K
2026-06-05LIN SUE-JEANn/aGrant6K$0.00$033K
2026-06-05Welgus Howard G.n/aGrant6K$0.00$038K
2026-06-05Leonard Keith Rn/aGrant6K$0.00$028K
2026-06-05Curran Terrien/aGrant6K$0.00$024K
2026-06-05Munshi Amitn/aGrant6K$0.00$010K
2026-06-05Gilbert Halley En/aGrant6K$0.00$028K
2026-06-05Krishnamohan Nehan/aGrant6K$0.00$028K
2026-05-11Vairavan LathaSVP Chief Financial OfficerSell435$21.05$9K86K
2026-05-11Burnett PatrickSee RemarksSell222$21.05$5K120K
2026-05-04Vairavan LathaSVP Chief Financial OfficerSell1K$23.61$32K86K
2026-05-04Watanabe ToddSee RemarksSell3K$23.61$75K721K
2026-05-04Matsuda MasaruSee RemarksSell884$23.61$21K127K
2026-05-04Matsuda MasaruSee RemarksSell7K$23.27$172K128K
2026-05-04Burnett PatrickSee RemarksSell684$23.61$16K120K
2026-05-01Welgus Howard G.n/aSell7K$22.99$164K33K
2026-04-01Welgus Howard G.n/aSell10K$23.88$239K40K
2026-03-02Edwards Larry ToddSee RemarksSell103$25.91$3K175K
2026-03-02Edwards Larry ToddSee RemarksSell4K$25.16$90K175K
2026-03-02Watanabe ToddSee RemarksSell1K$25.91$28K786K

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.

13F holders

Tracked managers holding ARQT at their latest 13F. JSON

7 of the 30 tracked managers held ARQT at their latest 13F, $188.7M in total at quarter-end prices. D. E. Shaw & Co. is the largest at $103.6M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 3 cut.

FundQuarterSharesValueOf portfolioChange in shares
D. E. Shaw & Co.2026-06-303.9M$103.6M0.05%+1.5M
Citadel Advisors2026-06-301.3M$33.3M0.00%+1.2M
Two Sigma Investments2026-06-30664K$17.4M0.01%+430K
Millennium Management2026-06-30564K$14.8M0.01%+515K
Point72 Asset Management2026-06-30362K$9.5M0.01%-228K
AQR Capital Management2026-06-30330K$8.7M0.00%-138K
Renaissance Technologies2026-06-3058K$1.5M0.00%-383K

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

Financials

SEC XBRL, as filed. JSON

In Q2 2026 (quarter ended 2026-06-30) Arcutis Biotherapeutics, Inc. reported revenue of $129.9M, up 59.3% from the same quarter a year earlier, and net income of $15.0M (0.11 diluted EPS). In FY 2025 it generated -$5.6M of operating cash flow. As of 2026-06-30, cash was $34.1M against $108.9M of debt.

Cash
$34.1M
Debt
$108.9M
Equity
$220.6M
Total assets
$488.5M
Shares outstanding
125,691,961

Quarterly, last 8 quarters

QuarterPeriod endRevenueNet incomeMarginDiluted EPS
Q2 20262026-06-30$129.9M$15.0M11.6%0.11
Q1 20262026-03-31$105.4M-$11.3M-10.7%-0.09
Q4 2025derived2025-12-31$129.5Mn/an/an/a
Q3 20252025-09-30$99.2M$7.4M7.5%0.06
Q2 20252025-06-30$81.5M-$15.9M-19.5%-0.13
Q1 20252025-03-31$65.8M-$25.1M-38.1%-0.20
Q4 2024derived2024-12-31$71.4Mn/an/an/a
Q3 20242024-09-30$44.8M-$41.5M-92.8%-0.33

Fiscal years, with buybacks and dividends

Fiscal yearEndsRevenueNet incomeOperating cash flowCapexBuybacksDividends
FY 20252025-12-31$376.1Mn/a-$5.6M$686Kn/an/a
FY 20242024-12-31$196.5Mn/a-$112.2M$143Kn/an/a
FY 20232023-12-31$59.6Mn/a-$247.1M$428Kn/an/a
FY 20222022-12-31$3.7Mn/a-$257.7M$333Kn/an/a
FY 20212021-12-31n/an/a-$174.6M$995Kn/an/a

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.

What this page is

Arcutis Biotherapeutics, Inc. in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.

This page follows Arcutis Biotherapeutics, Inc. (ARQT), SEC CIK 1787306, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.

Source and method

Short interest
FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
Daily short volume
FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
Fails to deliver
SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-11.JSON and CSV
13F holders
SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
Financials
SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
Insider trades
SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-09-08.JSON and CSV
Company record
EDGAR filing index for CIK 1787306Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits
30 requests a minute without a key, 120 a minute with a key from a free account.

Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 13 Sep 05:40 UTC.

How to read it

  • Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
  • Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
  • Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Other companies the SEC classifies as pharmaceutical preparations

Datasets

Frequently Asked Questions

How much of ARQT is sold short?
14,717,905 shares were held short at the 2026-08-14 settlement, 8.0 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ARQT's daily short volume?
On 2026-09-11, 405,687 of the 721,570 ARQT shares reported to FINRA were sold short, 56.2% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ARQT have fails to deliver?
The SEC's latest file shows 16 ARQT shares failed to deliver at settlement 2026-08-11. Fails are reported per settlement date and published twice a month with a lag.
Are ARQT insiders buying or selling?
Insiders at ARQT reported 15 open-market sells worth $2.3M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Matsuda Masaru (See Remarks) on 2026-09-08.
What did ARQT report last quarter?
In Q2 2026 (quarter ended 2026-06-30) Arcutis Biotherapeutics, Inc. reported revenue of $129.9M, up 59.3% from the same quarter a year earlier, and net income of $15.0M (0.11 diluted EPS). In FY 2025 it generated -$5.6M of operating cash flow. As of 2026-06-30, cash was $34.1M against $108.9M of debt.
Which funds hold ARQT?
7 of the 30 tracked managers held ARQT at their latest 13F, $188.7M in total at quarter-end prices. D. E. Shaw & Co. is the largest at $103.6M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 3 cut.

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.